Thus, MSC-delivered sTRAIL in combination with AKTi is a potential option for advanced prostate cancer with PTEN mutations/deletions, but other combinations may be necessary in a cancer-specific, or even patient-specific, manner. The gene discussed is PTEN; the disease is prostate cancer.